Pathology

Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer's Disease at Discovery Europe 2024

Retrieved on: 
Martedì, Maggio 14, 2024
Patient, Congress Center Basel, Basil, Hope, LRRK2, Discovery, LEHI, Impact, Neurodegenerative disease, Therapy, Conference, AI, Alzheimer's disease, Caregiver, Pathology, Drug discovery, Inflammation, RAB10, Pharmaceutical industry

David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland.

Key Points: 
  • David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland.
  • HT-4253 targets Leucine-Rich Repeat Kinase 2 (LRRK2) protein, which Halia has identified as a key player in regulating RAB10, a critical factor in the progression of Alzheimer's disease.
  • "As part of our participation, we are delighted to unveil and present data on our HT-4253 clinical program, representing a paradigm shift in Alzheimer's disease treatment.
  • For more information on the congress please visit: https://oxfordglobal.com/discovery/events/discovery-europe-2024
    Halia Therapeutics is unwavering in its commitment to advancing the HT-4253 program through rigorous clinical development.

Prestigious Colombian university hospital first to use Sectra's enterprise imaging solution in Latin America

Retrieved on: 
Martedì, Maggio 14, 2024
International, Research, Pathology, Diagnosis, City, KLAS, VNA, Radiology, Medical imaging

LINKÖPING, Sweden, May 14, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) enterprise imaging solution has been selected by the university hospital Hospital Universidad del Norte, in Colombia.

Key Points: 
  • LINKÖPING, Sweden, May 14, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) enterprise imaging solution has been selected by the university hospital Hospital Universidad del Norte, in Colombia.
  • As part of their journey to unify medical imaging across the hospital, they will start by streamlining radiology workflows and enhance reporting efficiency.
  • The contract for Sectra's enterprise imaging solution was signed in the fourth quarter of Sectra's 2023/2024 fiscal year and the hospital will initially utilize the solution's radiology module.
  • Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs.

Cerebrum Announces Integration Support with Sakura Finetek Products

Retrieved on: 
Lunedì, Maggio 13, 2024
LIS, Microtome, Health, ISH, Marketing, Cerebrum, Laboratory information management system, TAT, Dermatology, Pathology, IHC, Communication, ASCP, Laboratory, HL7

PHOENIX, May 13, 2024 /PRNewswire-PRWeb/ -- Cerebrum™, a leading provider of Laboratory Information System (LIS) software, announced new capabilities and a collaboration with Sakura Finetek USA to support anatomic pathology labs increasing productivity and overall workflow. Cerebrum's LABdivus® now supports complete integration with Sakura Finetek USA's Tissue-Tek AutoTEC® a120 Automated Embedding System and Tissue-Tek Genie® Advanced Staining System.

Key Points: 
  • Cerebrum™ - Sakura Finetek integration saves customers time, reduces errors
    PHOENIX, May 13, 2024 /PRNewswire-PRWeb/ -- Cerebrum™, a leading provider of Laboratory Information System (LIS) software, announced new capabilities and a collaboration with Sakura Finetek USA to support anatomic pathology labs increasing productivity and overall workflow.
  • Cerebrum's LABdivus® now supports complete integration with Sakura Finetek USA's Tissue-Tek AutoTEC® a120 Automated Embedding System and Tissue-Tek Genie® Advanced Staining System.
  • Cerebrum also released Cerebrum Connect™, a configurable middleware program, to connect the Tissue-Tek AutoTEC a120 and Tissue-Tek Genie to alternative laboratory information systems (LIS) through HL7 interfacing.
  • Pricing for Cerebrum Connect can be found on the Cerebrum website, www.cerebrumcorp.com
    "This integration is a game-changer for our lab.

Alzheimer's Drug Discovery Foundation (ADDF) and Association for Frontotemporal Degeneration (AFTD) Extend Treat FTD Fund Through 2035

Retrieved on: 
Lunedì, Maggio 13, 2024
Fillit, Patient, Doctor of Philosophy, Hope, Dementia, Alzheimer's disease, Pathology, FTD, Lewy body dementias, Treat, Disease, Safety, Registry, Lauder, MD, Growth, Research, Therapy, Frontotemporal dementia, Entrepreneurship, Pharmaceutical industry

NEW YORK, May 13, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today the extension of the Treat FTD Fund through 2035 that was made possible from additional funding from the Lauder and Newhouse families. This 10-year, $10 million commitment will provide critical funding for frontotemporal dementia (FTD) trials, which will advance new therapies and repurposed drugs, ultimately helping the 1.5 million patients living with FTD globally. FTD, a historically underfunded disease focus-area, encompasses a spectrum of neurodegenerative diseases with varied biological mechanisms, clinical symptoms and prognoses that come with unique challenges for clinical drug development.

Key Points: 
  • NEW YORK, May 13, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today the extension of the Treat FTD Fund through 2035 that was made possible from additional funding from the Lauder and Newhouse families.
  • This 10-year, $10 million commitment will provide critical funding for frontotemporal dementia (FTD) trials, which will advance new therapies and repurposed drugs, ultimately helping the 1.5 million patients living with FTD globally.
  • FTD, a historically underfunded disease focus-area, encompasses a spectrum of neurodegenerative diseases with varied biological mechanisms, clinical symptoms and prognoses that come with unique challenges for clinical drug development.
  • Started in 2016, the Treat FTD Fund has invested $7 million in early-stage clinical trials, testing novel and repurposed disease-modifying drugs, as well as therapeutics for FTD symptom management.

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
Mercoledì, Maggio 8, 2024
Neurodegenerative disease, Neuroimaging, MSA, Safety, Pharmacokinetics, Food, ASX, Pathology, Disease, Data monitoring committee, Patient, DMC, Biomarker, Clinical trial, Therapy, ATH, Food and Drug Administration, SAN, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Martedì, Maggio 7, 2024
Electrode, OCD, Obsessions, Pathology, Psychiatry, Patient, Brain, Deep brain stimulation, Assistant, Biomarker, Therapy, Quality of life

New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on Tuesday, May 14, 2024, at 2:00 pm ET.

Key Points: 
  • New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on Tuesday, May 14, 2024, at 2:00 pm ET.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds is the webinar host.
  • Register today at BBRFoundation.org
    Obsessive-compulsive disorder (OCD) is a long-lasting disorder in which a person experiences uncontrollable and recurring thoughts (obsessions), engages in repetitive behaviors (compulsions), or both.
  • Treatment success, however, depends in part on personalized adjustment of deep-brain stimulation after the electrodes have been implanted.

Azra AI Appoints John Marshall as New CEO

Retrieved on: 
Mercoledì, Maggio 8, 2024
Data Management, Technology, Managed Care, Other Health, Health, Oncology, Health Technology, Software, Artificial Intelligence, Hospitals, Internet, Cancer, ROI, Azra, Hospital, Pathology, Artificial intelligence, Software as a service, History, IPO, Radiology, Medical Education Number, Patient, Acquisition, Data management, Multimedia, Internationalized domain name

Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.

Key Points: 
  • Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.
  • Marshall will succeed Chris Cashwell, who will continue to support Azra as an advisor.
  • "Given the increasing demand for AI-driven healthcare solutions, John Marshall is the ideal leader to propel Azra AI to new heights.
  • With John Marshall's strategic leadership and focus on expanding the platform's innovative capabilities, Azra AI will continue to drive impactful improvements in operational efficiency, patient care, and service line growth across the healthcare industry.

Marwood Group Hires Nayan Ghosh to Head Life Sciences & HealthTech Practice

Retrieved on: 
Mercoledì, Maggio 8, 2024
Health, Health Insurance, Nayan, FDA, Policy, Commercial, Pathology, Depression, Disease, Patient, Diagnosis, Therapy, Growth, Head, Pharmaceutical industry

Marwood Group , a leading, global healthcare advisory firm known for its deep expertise at the intersection of healthcare policy and commercial strategy, announced today the appointment of Nayan Ghosh as Director, Head of Life Sciences & HealthTech.

Key Points: 
  • Marwood Group , a leading, global healthcare advisory firm known for its deep expertise at the intersection of healthcare policy and commercial strategy, announced today the appointment of Nayan Ghosh as Director, Head of Life Sciences & HealthTech.
  • After first joining Marwood in 2017 to help expand the market access and commercial strategy capabilities of the Life Sciences & HealthTech practice , Ghosh took a hiatus in 2021 to serve as Head of Commercial & Regulatory Strategy at Arcade Therapeutics, targeting some of the first FDA authorizations for non-drug anxiety and depression treatments.
  • “Over the last decade, Marwood’s focus on Life Sciences & HealthTech has grown significantly, driven by its synergy with Marwood’s deep expertise, data and analytics capabilities related to healthcare services and delivery.
  • “The mission of Marwood’s Life Sciences & HealthTech practice is to help life-changing healthcare innovations get into the hands of the patients and practitioners who need them,” said Ghosh.

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
Martedì, Maggio 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

South Africa Funeral Services Report 2024, with 22 Company Profiles Including AVBOB, Doves, Martin's Funerals, Icebolethu, Total Funeral Logistics, Calgro M3 and Independent Crematoriums SA - ResearchAndMarkets.com

Retrieved on: 
Martedì, Maggio 7, 2024
Religion, SME, Policy, Cremation, Death, Pathology, Culture, Funeral, Pressure, Private sector, Burial, Government, Funeral home, Growth, Cemetery, Life insurance

The "Funeral Services and Related Activities in South Africa 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Funeral Services and Related Activities in South Africa 2024" report has been added to ResearchAndMarkets.com's offering.
  • A global research study identified South Africa as the fourth most expensive country in terms of funeral costs, which were 3% above the global average.
  • The South African Funeral Practitioners Association has called on government to regulate the funeral services sector.
  • This report focuses on the funeral services and related activities sector in South Africa.